Washington, D.C. 20549

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 10, 2020

(Exact name of registrant as specified in its charter)

Registrant’s telephone number, including area code: +972.4.959.0123

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Item 2.02 Results of Operations and Financial Condition.

 

On November 10, 2020, ReWalk Robotics Ltd. (the “Company,” “we” or “us”) issued a press release announcing its financial results for the third quarter ended September 30, 2020. A copy of the press release is being furnished herewith as Exhibit 99.1. As set forth in the press release, the Company hosted a conference call to discuss its financial results for the third quarter ended September 30, 2020 on November 10, 2020 at 8:30 a.m. E.D.T. The archived webcast will be available at https://edge.media-server.com/mmc/p/ou3s2suj and/or through the Company’s website at www.rewalk.com under the “Investors” section for 30 days after the completion of the call.

 

The information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “1934 Act”), nor shall it be deemed “incorporated by reference” into any filing under the Securities Act of 1933, as amended, or the 1934 Act, except as may be expressly set forth by specific reference in such filing.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits
99.1	Press release dated November 10, 2020 of ReWalk Robotics Ltd., announcing financial results for the third quarter ended September 30, 2020.*
*	Furnished herewith

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

ReWalk Robotics Reports Third Quarter 2020 Financial Results

 
MARLBOROUGH, Mass. BERLIN, Germany and YOKNEAM ILIT, Israel, November 10, 2020 - ReWalk Robotics Ltd. (Nasdaq: RWLK) (“ReWalk” or the “Company”) today announced its financial results for the three and nine months ended September 30, 2020.

 

•

Total revenue for the third quarter of 2020 was $0.7 million, compared to $1.2 million in the prior year quarter;

•

Received Medicare Provider certification from the Centers for Medicare & Medicaid Services ("CMS");

•

Completed additional contract with a German payor; and

•

Raised total of approximately $9.0 million in gross proceeds from a registered direct offering of ordinary shares and a concurrent private placement of unregistered warrants to purchase ordinary shares (as previously referenced in ReWalk’s Second Quarter 2020 Financial Results).

The archived webcast will be available via the following URL https://edge.media-server.com/mmc/p/ou3s2sujor through the 'Investors—Webcasts & Presentations' section on www.rewalk.com.

 

About ReWalk Robotics Ltd.

 

ReWalk Robotics Ltd. develops, manufactures, and markets wearable robotic exoskeletons for individuals with lower limb disabilities as a result of spinal cord injury or stroke.  ReWalk’s mission is to fundamentally change the quality of life for individuals with lower limb disability through the creation and development of market leading robotic technologies. Founded in 2001, ReWalk has headquarters in the U.S., Israel, and Germany. For more information on the ReWalk systems, please visit www.rewalk.com.

 

ReWalk® is a registered trademark of ReWalk Robotics Ltd. in Israel and the United States.

In addition to historical information, this press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the U.S. Securities Act of 1933, and Section 21E of the U.S. Securities Exchange Act of 1934. Such forward-looking statements may include projections regarding ReWalk's future performance and other statements that are not statements of historical fact and, in some cases, may be identified by words like "anticipate," "assume," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "future," "will," "should," "would," "seek" and similar terms or phrases. The forward-looking statements contained in this press release are based on management's current expectations, which are subject to uncertainty, risks and changes in circumstances that are difficult to predict and many of which are outside of ReWalk's control. Important factors that could cause ReWalk's actual results to differ materially from those indicated in the forward-looking statements include, among others: ReWalk's management's conclusion, and its independent registered public accounting firm's statement in its opinion relating to its consolidated financial statements for the fiscal year ended December 31, 2019, that there is a substantial doubt as to the Company's ability to continue as a going concern; the current COVID-19 pandemic has adversely affected and may continue to affect adversely  business and results of operations; ReWalk's ability to have sufficient funds to meet certain future capital requirements, which could impair the Company's efforts to develop and commercialize existing and new products; ReWalk's ability to maintain compliance with the continued listing requirements of the Nasdaq Capital Market and the risk that its ordinary shares will be delisted if it cannot do so; ReWalk's ability to establish a pathway to commercialize its products in China; ReWalk's ability to maintain and grow its reputation and the market acceptance of its products; ReWalk's ability to achieve reimbursement from third-party payors for its products; ReWalk's limited operating history and its ability to leverage its sales, marketing and training infrastructure; ReWalk's expectations as to its clinical research program and clinical results; ReWalk's expectations regarding future growth, including its ability to increase sales in its existing geographic markets and expand to new markets; ReWalk's ability to obtain certain components of its products from third-party suppliers and its continued access to its product manufacturers; ReWalk's ability to repay its secured indebtedness; ReWalk's ability to improve its products and develop new products; ReWalk's compliance with medical device reporting regulations to report adverse events involving the Company's products, which could result in voluntary corrective actions or enforcement actions such as mandatory recalls, and the potential impact of such adverse events on ReWalk's ability to market and sell its products; ReWalk's ability to gain and maintain regulatory approvals; ReWalk's expectations as to the results of, and the Food and Drug Administration's potential regulatory developments with respect to its mandatory 522 postmarket surveillance study; ReWalk's ability to maintain adequate protection of its intellectual property and to avoid violation of the intellectual property rights of others; the risk of a cybersecurity attack or breach of the Company's IT systems significantly disrupting its business operations; the impact of substantial sales of the Company's shares by certain shareholders on the market price of the Company's ordinary shares; ReWalk's ability to use effectively the proceeds of its offerings of securities; the risk of substantial dilution resulting from the periodic issuances of ReWalk's ordinary shares; the impact of the market price of the Company's ordinary shares on the determination of whether it is a passive foreign investment company; and other factors discussed under the heading "Risk Factors" in ReWalk's annual report on Form 10-K for the year ended December 31, 2019 filed with the SEC and other documents subsequently filed with or furnished to the SEC. Any forward-looking statement made in this press release speaks only as of the date hereof. Factors or events that could cause ReWalk's actual results to differ from the statements contained herein may emerge from time to time, and it is not possible for ReWalk to predict all of them. Except as required by law, ReWalk undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.

 

Non-GAAP Financial Measures

 

To supplement its consolidated financial statements, which are prepared and presented in accordance with U.S. Generally Accepted Accounting Principles (GAAP), ReWalk believes that the use of non-GAAP accounting measures, including non-GAAP net loss, is helpful to its investors. These measures, which the Company refers to as non-GAAP financial measures, are not prepared in accordance with GAAP.

 

For the three and nine months ended September 30, 2020 and 2019, non-GAAP net loss is calculated as GAAP net loss excluding (i) non-cash share-based compensation expense, (ii) depreciation and (iii) non-cash financial expenses.

 

Because of varying available valuation methodologies, subjective assumptions, and the variety of equity instruments that can impact a company’s non-cash expenses, ReWalk believes that providing non-GAAP financial measures that exclude non-cash share-based compensation expense, depreciation and non-cash financial (income) expenses allows for more meaningful comparisons between operating results from period to period. Each of the Company’s non-GAAP financial measures is an important tool for financial and operational decision-making and for the Company’s evaluation of its operating results over different periods of time. The non-GAAP financial data are not measures of the Company’s financial performance under U.S. GAAP, and should not be considered as alternatives to operating loss or net loss or any other performance measures derived in accordance with GAAP. Non-GAAP financial measures may not provide information that is directly comparable to that provided by other companies in ReWalk’s industry, as other companies in the industry may calculate non-GAAP financial results differently, particularly related to non-recurring, unusual items. In addition, there are limitations in using non-GAAP financial measures because the non-GAAP financial measures are not prepared in accordance with GAAP, may be different from non-GAAP financial measures used by other companies and exclude expenses that may have a material impact on the Company’s reported financial results. Further, share-based compensation expense has been, and will continue to be for the foreseeable future, a significant recurring expense in the Company’s business and an important part of the compensation provided to its employees.

 

The presentation of non-GAAP financial information is not meant to be considered in isolation or as a substitute for the directly comparable financial measures prepared in accordance with GAAP. ReWalk urges investors to review the reconciliation of the Company’s non-GAAP financial measures to the comparable GAAP financial measures included below, and not to rely on any single financial measure to evaluate the Company’s business.

 

Investor Contact:
Ori Gon

Chief Financial Officer 
ReWalk Robotics Ltd.
T: +972-4-9590123 
E: investorrelations@rewalk.com

		Three Months Ended								Nine Months Ended
		September 30,								September 30,
		2020				2019				2020				2019
Revenue		$	747			$	1,234			$	3,175			$	3,692
Cost of revenues			355				585				1,388				1,682
Gross profit			392				649				1,787				2,010
Operating expenses:
Research and development, net			756				1,018				2,695				4,292
Sales and marketing			1,507				1,453				4,541				4,571
General and administrative			1,198				1,209				3,774				3,988
Total operating expenses			3,461				3,680				11,010				12,851
Operating loss			(3,069	)			(3,031	)			(9,223	)			(10,841	)
Financial expenses, net			242				360				723				1,131
Loss before income taxes			(3,311	)			(3,391	)			(9,946	)			(11,972	)
Taxes on income (tax benefit)			25				(2	)			85				4
Net loss		$	(3,336	)		$	(3,389	)		$	(10,031	)		$	(11,976	)
Net loss per ordinary share, basic and diluted		$	(0.18	)		$	(0.46	)		$	(0.71	)		$	(2.27	)
Weighted average number of shares used in computing net loss per ordinary share, basic and diluted			18,881,694				7,290,791				14,132,375				5,284,451
Reconciliation of GAAP to Non-GAAP net loss
Net loss		$	(3,336	)		$	(3,389	)		$	(10,031	)		$	(11,976	)
Non-cash share based compensation expense			232				236				544				869
Depreciation of property and equipment, net			64				69				215				242
Non-cash financial expenses			59				-				59				-
Non-GAAP net loss		$	(2,981	)		$	(3,084	)		$	(9,213	)		$	(10,865	)

		September 30,				December 31,
		2020				2019
Assets
Current assets
Cash and cash equivalents		$	18,050			$	16,253
Trade receivable, net			715				794
Prepaid expenses and other current assets			833				903
Inventories			3,707				3,123
Total current assets			23,305				21,073
Restricted cash and other long term assets			1,034				1,061
Operating lease right-of-use assets			1,421				1,737
Property and equipment, net			474				501
Total assets		$	26,234			$	24,372
Liabilities and equity
Current liabilities
Current maturities of long term loans		$	3,280			$	5,438
Current maturities of operating leases			622				637
Trade payables			2,107				2,698
Other current liabilities			1,636				1,395
Total current liabilities			7,645				10,168
Long term loan, net of current maturities			154				1,527
Noncurrent operating leases			985				1,315
Other long-term liabilities			661				582
Shareholders’ equity			16,789				10,780
Total liabilities and equity		$	26,234			$	24,372

		Nine Months Ended
		September 30,
		2020				2019
Net cash used in operating activities		$	(10,131	)		$	(11,225	)
Net cash used in investing activities			(73	)			(8	)
Net cash provided by financing activities			11,948				22,033
Increase in cash, cash equivalents, and restricted cash			1,744				10,800
Cash, cash equivalents, and restricted cash at beginning of period			16,992				10,347
Cash, cash equivalents, and restricted cash at end of period		$	18,736			$	21,147

		Three Months Ended								Nine Months Ended
		September 30,								September 30,
		2020				2019				2020				2019
		(Unaudited)								(Unaudited)
Revenue:
Israel		$	-			$	-			$	-			$	2
United States			325				569				1,172				1,492
Europe			413				665				1,990				2,162
Asia Pacific			2				-				6				36
Latin America			6				-				6				-
Africa			1				-				1				-
Total Revenue		$	747			$	1,234			$	3,175			$	3,692
Revenue:
Personal units revenue		$	698			$	1,127			$	3,079			$	3,524
Rehabilitation units revenue			49				107				96				168
Total Revenue		$	747			$	1,234			$	3,175			$	3,692

---